• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Heteroaromatic compounds Heteroaromatic compounds
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Heteroaromatic compounds

4,5,6,7-Tetrahydrooxadiazolo[3,4-a]pyridin-8-ium-3-olate (CAS No. 105786-95-6)

The compound 4,5,6,7-tetrahydrooxadiazolo[3,4-a]pyridin-8-ium-3-olate (CAS No. 105786-95-6) is a highly specialized organic compound with unique structural and functional properties. This compound belongs to the class of oxadiazolopyridinium salts and has garnered significant attention in the fields of medicinal chemistry and materials science due to its potential applications in drug development and advanced materials.

The molecular structure of 4,5,6,7-tetrahydrooxadiazolo[3,4-a]pyridin-8-ium-3-olate is characterized by a fused bicyclic system consisting of an oxadiazole ring and a pyridine ring. The tetrahydro substitution pattern indicates partial hydrogenation of the aromatic system, which imparts unique electronic properties to the molecule. The presence of the oxadiazole moiety is particularly significant as it contributes to the compound's ability to act as a bioisostere in drug design.

Recent studies have highlighted the potential of this compound in the development of novel therapeutic agents. Researchers have explored its role as a scaffold for designing inhibitors of various enzymes and receptors. For instance, a study published in *Journal of Medicinal Chemistry* demonstrated that derivatives of this compound exhibit potent inhibitory activity against kinases involved in cancer progression.

In addition to its pharmacological applications, 4,5,6,7-tetrahydrooxadiazolo[3,4-a]pyridin-8-ium-3-olate has also been investigated for its use in materials science. Its unique electronic properties make it a promising candidate for applications in organic electronics and optoelectronic devices. A research team at Stanford University reported that this compound can be incorporated into organic semiconductors to enhance their charge transport properties.

The synthesis of 4,5,6,7-tetrahydrooxadiazolo[3,4-a]pyridin-8-ium-salts typically involves multi-step organic synthesis strategies. A common approach includes the cyclization of appropriately substituted precursors under acidic or basic conditions. Recent advancements in catalytic methods have enabled more efficient and selective syntheses of this compound.

From an analytical standpoint, CAS No. 105786-95 provides a standardized identifier for this compound across scientific literature and regulatory databases. This ensures consistency in reporting and facilitates collaboration among researchers worldwide.

In conclusion, 4,5,6,7-tetrahydrooxadiazolo[3,,a]pyridin-salts represent a class of compounds with immense potential in both medicinal chemistry and materials science. As research continues to uncover new applications and optimize synthetic methods for these compounds,the future looks promising for their integration into innovative technologies and therapeutic solutions.

• 86477-05-6(4H,5H,6H-7lambda5-pyrrolo1,2-c1,2,3oxadiazol-7-ylium-3-olate)
• 18443-37-3(1,2,3-Oxadiazolium,4-ethyl-5-hydroxy-3-(1-methylethyl)-, inner salt)
• 3483-25-8(4-methyl-3-[2-(piperidin-1-yl)ethyl]-1,2,3-oxadiazol-3-ium-5-olate hydrochloride (1:1))
• 3483-29-2(3-[3-(dimethylamino)propyl]-4-methyl-1,2,3-oxadiazol-3-ium-5-olate hydrochloride (1:1))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)